Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Anti-Platelet Therapy In PCI - ACC 2018 - ADAPT
Author(s): Jay Giri Added: 5 years ago
Jay Giri discusses ADAPT - Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention. Filmed by Radcliffe Cardiology on-site at the American College of Cardiology congress 2018 in Orlando, USA. View more

Prevention & Chronic Conditions
Author(s): Donald E Cutlip Added: 3 years ago
Stent thrombosis has been recognized as a serious complication of coronary stent placement since the procedure was first reported in the 1980s.1 Subsequent aggressive peri-procedural anti-thrombotic strategies with inpatient transition to warfarin reduced the risk to about 3.5 % for subacute (30-day) stent thrombosis,2,3 a rate that would be unacceptable by current standards and did not account… View more

Prevention & Chronic Conditions

Intervention
Author(s): Victor L Serebruany Added: 3 years ago
Understanding of the pathogenesis of congestive heart failure (CHF) has improved remarkably in recent years. However, despite better knowledge and novel pharmaceutical strategies, this disease is still one of the most brutal killers in the Western world. The pathophysiology of CHF is complex, and much of our comprehension revolves strictly around the neurohormonal and mechanical mechanisms… View more

Heart Failure
Author(s): Victor L Serebruany Added: 3 years ago
Understanding of the pathogenesis of congestive heart failure (CHF) has improved remarkably in recent years. However, despite better knowledge and novel pharmaceutical strategies, this disease is still one of the most brutal killers in the Western world. The pathophysiology of CHF is complex, and much of our comprehension revolves strictly around the neurohormonal and mechanical mechanisms… View more

Anticoagulation
ESC 22: COVID-PACT: Antithrombotic Therapy in Critically Ill COVID-19 Pts
Author(s): David Berg Added: 1 year ago
ESC Congress 22 — Dr David Berg (Brigham and Women's Hospital, US) shares key results from the TIMI Study Group's COVID-PACT trial (NCT04409834). This multicenter, randomized-controlled trial assessed efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events. The study… View more

Anticoagulation

Vascular Disease and Surgery
Research Area(s) / Expertise:

Inherited and Congenital Cardiac Conditions
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart… View more
AHA 21: AXIOMATIC-TKR: Patients Treated with Milvexian Show Reduced Rate of Venous Thromboembolism
Author(s): Jeffrey Weitz Added: 2 years ago
Dr Jeffrey Weitz (Thrombosis & Atherosclerosis Research Institute, Ontario, CA) presents the results of the Axiomatic-TKR Study, a phase II dose-ranging study that aims to examine the effect of Milvexian versus Enoxaparin in the treatment of venous thromboembolism in patients undergoing total-knee replacement surgery.The study met its efficacy criteria, where the rate of thromboembolism was… View more

Vascular Disease and Surgery
Author(s): Gaku Nakazawa , Aloke V Finn , Renu Virmani Added: 3 years ago
Polymer-based sirolimus (Cypher®) and paclitaxel (Taxus®) drug-eluting stents (DES) have reduced rates of restenosis and target lesion revascularization (TLR) compared with bare-metal stents (BMS) and have launched a revolution in the interventional treatment of symptomatic coronary artery disease.1,2 However, this overwhelming enthusiasm has recently been dampened by safety concerns regarding a… View more

Anticoagulation

Intervention
Author(s): Donald E Cutlip Added: 3 years ago
Dual anti-platelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces recurrent ischemic events in patients with acute coronary syndrome and is recommended by guidelines for patients treated with either an early invasive or ischemia-guided strategy.1,2 For initial therapy, either clopidogrel or ticagrelor are the preferred options, with prasugrel also an option at the time of percutaneous… View more

Anticoagulation
Author(s): Peter J Fitzgerald , Martin B Leon Added: 3 years ago
An unintended consequence of the market success of drug-eluting stents has been a growing concern about their safety and safety-related costs. These devices have been so quickly and widely adopted that their market penetration already equals that of some of the most popular pharmaceutical drugs. Consequently, the absolute significance of even a low incidence of side effects becomes magnified by… View more

Intervention